Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035227 | 0.90 | LMNA (0.36) | LMNA | |
| SCHEMBL5380398 | 0.85 | PPARG (0.34) | LMNA | |
| SCHEMBL5376445 | 0.83 | PPARG (0.34) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL6035085 | 0.82 | PPARD (0.45) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL4033999 | 0.78 | KDM4E (0.40) | LMNAL3MBTL1 | |
| SCHEMBL4036792 | 0.68 | MAPT (0.52) | LMNA | |
| SCHEMBL24724187 | 0.65 | FFAR1 (0.66) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL1206782 | 0.65 | KDM4E (0.75) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL3689839 | 0.64 | FFAR1 (0.64) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL24723648 | 0.64 | FFAR1 (0.64) | FFAR1FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | FFAR1 376/4885FFAR4 195/4885LMNA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.